|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BRIEF DEFINITIVE REPORT |
CORRESPONDENCE Atsushi Iwama: aiwama{at}faculty.chiba-u.jp OR Hiromitsu Nakauchi: nakauchi{at}ims.u-tokyo.ac.jp
|
|
|---|
One of the major Bmi1 targets is the Ink4a/Arf locus (9). This locus encodes a cyclin-dependent kinase inhibitor, p16Ink4a, and a tumor suppressor, p19Arf. p16Ink4a inhibits the binding of cyclin D to Cdk4/6 and keeps retinoblastoma protein (Rb) hypophosphorylated. Hypophosphorylated Rb represses E2F-dependent transcription by sequestrating E2F, ultimately leading to cell cycle arrest or senescence. p19Arf inhibits MDM2 and ARF-BP1, which mediate the ubiquitin-dependent degradation of p53, leading to the accumulation of p53 protein. This results in activation of the p53 target genes involved in cell cycle arrest, apoptosis, or senescence (10). In Bmi1-deficient mice, the expression of Ink4a and Arf is markedly increased in hematopoietic cells (7, 8), and the enforced expression of Ink4a and Arf in HSCs resulted in cell cycle arrest and p53-dependent apoptosis, respectively (7). Conversely, Bmi1;Ink4a/Arf compound mutant mice (hereafter referred to as Bmi1/Ink4a-Arf/ mice) exhibited a substantial recovery of hematopoietic cells, as indicated by restored lymphocyte counts (9, 11), as well as of the self-renewal capacity of neural stem cells (11, 12). However, the real impact of derepressed Ink4a and Arf in self-renewing HSCs has not yet been determined using a genetic approach.
To address this question, we performed a detailed analysis of HSCs in Bmi1/Ink4a-Arf/ mice and identified a critical role for Bmi1-dependent repression of the p16Ink4aRb and p19Arfp53 pathways in the maintenance of self-renewing HSCs. We further demonstrated evidence of the involvement of Bmi1 in the regulation of HSCs and their BM microenvironment in a way that is not associated with the Ink4a and Arf locus.
| RESULTS AND DISCUSSION |
|---|
|
|
|---|
|
To further evaluate the proliferative and differentiation capacity of Bmi1/Ink4a-Arf/ HSCs, we purified the CD34KSL HSC fraction, and an in vitro single-cell culture was performed for 14 d in the presence of stem cell factor (SCF), IL-3, thrombopoietin (TPO), and erythropoietin (EPO). Although Bmi1/ HSCs contained 3.3-fold fewer high proliferative potential (HPP) colony-forming cells (CFCs) than the wild type, Bmi1/Ink4a-Arf/ HSCs contained a comparable number of HPP-CFCs with the wild type (Fig. 2 A). We have previously demonstrated that CFU-neutrophil/macrophage/erythroblast/megakaryocyte (nmEM), which retains multilineage differentiation capacity, is a major subpopulation among CD34KSL HSCs but not among CD34+KSL multipotential progenitor cells and that its frequency is well correlated with that of functional HSCs (14). Of note, the morphological analysis of HPP colonies revealed that Bmi1/ CD34KSL cells present a drastic reduction in their frequency of CFU-nmEM, whereas Bmi1/Ink4a-Arf/ HSCs show a substantial recovery in their frequency of CFU-nmEM compared with the wild type (Fig. 2 B). In an in vitro culture of pooled CD34KSL HSCs, however, Bmi1/Ink4a-Arf/ HSCs exhibited a considerable but only partial recovery of proliferation (Fig. 2 C). In vitro culture systems are a kind of stringent condition in which numerous signaling entities are missing that are supportive for HSCs and are present in the in vivo microenvironment. Thus, these findings suggest that the deletion of Ink4a and Arf does not completely restore the defective proliferative and differentiation capacity of Bmi1/ HSCs.
|
|
|
To further characterize the role of Bmi1 in osteoblasts as niche cells, we analyzed primary cultured Bmi1/ osteoblasts. Bmi1/ osteoblasts showed a normal level of alkaline phosphatase activity, which is one of the representative osteoblastic differentiation markers (Fig. S3 A, available at http://www.jem.org/cgi/content/full/jem.20052477/DC1). RT-PCR analysis of the osteoblast-specific marker genes (Osteopontin, Osteocalcin, Runx2, Ostetix, and Col1a1) as well as known HSC niche factor genes (N-cadherin, Angiopoietin-1, -2, Jagged-1, and SCF) was unable to discern any gross difference between the wild-type and Bmi1/ osteoblasts, although p16Ink4a and p19Arf were also derepressed in Bmi1/ osteoblasts (Fig. S3 B). We then took advantage of the Bmi1 knockdown technique. Osteoblasts were infected with a lentivirus expressing short hairpin RNA (shRNA) against Bmi1, which efficiently inhibited the transcription of Bmi1 (Fig. 4 F). Consistent with in vivo trabecular bone formation, Bmi1 knockdown led to a reduced osteoblast proliferation (Fig. 4 F). Nonetheless, Bmi1 knockdown osteoblasts similarly supported the survival and multilineage differentiation capacity of CD34KSL HSCs during a 5-d ex vivo culture (Fig. S3 C). Collectively, these findings suggest that Bmi1 controls the BM microenvironment, at least in part, by regulating osteoblast niche size. In contrast with the case of HSCs, however, the deletion of both Ink4a and Arf again did not substantially restore the impaired development of the trabecular bone (Fig. 4 E) or the impaired proliferation of Bmi1 knockdown osteoblasts (Fig. 4 F), confirming that the Ink4a and Arf genes are not the major targets for Bmi1 in the maintenance of the BM microenvironment, as demonstrated in Fig. 4 (A and C). The BM microenvironment consists of not only osteoblasts but also stromal cells, endothelial cells (18), and so on. It would be intriguing to ask whether Bmi1 also functions in the other components of the BM microenvironment.
Our findings in this study clearly demonstrate that the derepression of Ink4a and Arf genes is responsible for defective HSC self-renewal. However, we have previously reported that Bmi1/ HSCs undergo the first cell division in a fashion similar to that of the wild type and showed no apoptosis in a single HSC culture. In addition, cell cycle analysis of BM primitive hematopoietic cells (KSL and Lin cells) did not detect any difference between the wild-type and Bmi1/ mice (8). These findings indicate that the derepression of Ink4a and Arf genes in Bmi1/ mice do not grossly affect the cell cycle or survival of HSCs.
It has been well recognized that the activated p16Ink4aRb and p19Arfp53 pathways are profoundly associated with cellular senescence (19). Cellular senescence is a program activated by normal cells in response to various types of stress. These include telomere attrition, DNA damage, oxidative stress, oncogenic stress, and others. Senescence of HSCs is supposed to be induced by telomere-dependent and -independent pathways (20, 21). We first measured the telomere length of wild-type and Bmi1/ lineage marker immature cells and lineage marker+ differentiated cells by fluorescence in situ hybridization. The loss of Bmi1 did not alter the telomere length at all (Fig. 5 A). In the absence of Bmi1, the derepression of Ink4a and Arf genes causes the premature senescence of mouse embryonic fibroblasts (9). Bmi1 knockdown osteoblasts indeed exhibited a higher senescence-associated (SA) ß-galactosidase activity, which was canceled in the absence of Ink4a and Arf genes (Fig. S4, available at http://www.jem.org/cgi/content/full/jem.20052477/DC1), suggesting that Bmi1 controls the cellular senescence of osteoblasts by regulating the expression of Ink4a and Arf genes. We then analyzed freshly isolated Bmi1/ CD34KSL HSCs in terms of the SAß-galactosidase activity and SA gene expression profiles, but all appeared negative (unpublished data). It is possible that the senescent HSCs do not express specific combinations of marker antigens for HSC identification any more. Thus, the possibility that derepressed Ink4a and Arf genes facilitate the premature senescence of HSCs remains to be determined.
|
Together, all of these observations implicate Bmi1 in both the cell-autonomous and nonautonomous regulation of the HSC system. Similar to BM hematopoiesis, an incomplete recovery of lymphocyte numbers in Bmi1/Ink4a-Arf/ mice could be ascribed to certain defects in the Bmi1/ microenvironment of the spleen and thymus (9, 11). Our findings further unveiled the differential impact of derepressed Ink4a and Arf on HSCs and their BM microenvironment in Bmi1-deficient mice, thus defining Ink4a and Arf as the major targets for Bmi1 in the maintenance of HSC self-renewal but not of the BM microenvironment.
Finally, Bmi1 has been demonstrated to be essential for the maintenance of leukemic stem cells in a mouse model of acute myelogenous leukemia induced by the Hoxa9-Meis1 fusion gene (5). It has also been demonstrated that the Rb and p53-dependent cellular senescence plays a critical role to oppose neoplastic transformation triggered by the activation of oncogenic pathways (19). It will be important to investigate whether the up-regulation of Bmi1 contributes to repression of the oncogene-induced senescence pathway in the leukemic transformation and maintenance of the self-renewal capacity of leukemic stem cells.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Competitive repopulation assay.
Hematopoietic cells from B6-Ly5.2 mice were mixed with BM competitor cells (B6-Ly5.1) and were transplanted into B6-Ly5.1 mice irradiated at a dose of 9.5 Gy. Donor cell chimerism in the recipient peripheral blood cells was evaluated as previously described (8). The ability of the Bmi1/ microenvironment to support hematopoiesis was evaluated by transplanting 2 x 106 wild-type BM cells (B6-Ly5.1) into 4-wk-old mutant mice (B6-Ly5.2) sublethally irradiated (Bmi1/ and Bmi1/Ink4a-Arf/ mice, 4.5 Gy; others, 6.5 Gy).
Purification of mouse HSCs and single-cell colony assay.
Mouse HSCs (CD34KSL cells) were purified from BM cells of 8-wk-old mice on a flow cytometry system (FACSVantage; Becton Dickinson) as previously described (8). Single CD34KSL cells were sorted clonally into 96-well plates containing 200 µl SF-O3 (Sanko Junyaku) supplemented with 5 x 105 M 2-ß-mercaptoethanol, 2 mM L-glutamine, 10% FBS, 20 ng/ml of mouse SCF, 20 ng/ml of mouse IL-3, 50 ng/ml of human TPO, and 1 unit/ml of human EPO (PeproTech).
Primary BM-derived osteoblast culture and Bmi1 knockdown.
Femurs and tibiae were cut into small pieces after BM cells were fully flushed out. Then, bone fragments were cultured in
-MEM supplemented with 2 mM L-glutamine, 10% FCS, and 5 x 105 M 2-ß-mercaptoethanol. Suspension cells were removed by replacing the medium. Osteoblastic phenotypes were evaluated by the expression of alkaline phosphatase. A lentivirus vector (CS-H1-shRNA-EF-1
-EGFP) expressing shRNA against mouse Bmi1 (target sequence TAAAGGATTACTACACGCTAATG) and Luciferase was prepared, and the viruses were produced as previously described (23).
RT-PCR.
Semiquantitative RT-PCR was performed using normalized cDNA with quantitative PCR using TaqMan rodent GAPDH control reagent (PerkinElmer) as previously described (8).
Quantification of telomere length.
Telomere length was quantified on a flow cytometer (FACSCalibur; BD Biosciences) using flow fluorescence in situ hybridization with a Telomere PNA Kit/FITC for flow cytometry (DakoCytomation).
Transduction of CD34KSL cells.
The retrovirus vector pGCDNsam-ires-EGFP (provided by M. Onodera, University of Tsukuba, Ibaraki, Japan), the production and concentration of recombinant retrovirus, and the transduction of CD34KSL cells have been described previously (8). After transduction, the cells were further incubated for 9 d in S-Clone SF-O3 supplemented with 5 x 105 M 2-ß-mercaptoethanol, 2 mM L-glutamine, 1% FBS, 50 ng/ml SCF, and 50 ng/ml TPO and subjected to in vitro colony assay using a methylcellulose medium (StemCell Technologies Inc.) supplemented with 20 ng/ml of mouse SCF, 20 ng/ml of mouse IL-3, 50 ng/ml of human TPO, and 1 unit/ml of human EPO. GFP+ colony numbers were counted on day 10. Colonies derived from HPP-CFCs (colony diameter of >1 mm) were recovered and morphologically examined. The transduction efficiency was >80% as judged from the GFP expression.
Online supplemental material.
Fig. S1 provides data for flow cytometric profiles and frequencies of HSCs in mutant mice. Fig. S2 provides data for the competitive BM repopulating assay using 10 times more test cells than the competitor cells. Fig. S3 provides data for differentiation and the HSC-supporting capacity of osteoblasts in the absence of Bmi1. Fig. S4 provides data for the senescence of Bmi1 knockdown osteoblasts. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20052477/DC1.
| Acknowledgments |
|---|
This work was supported, in part, by grants from the Ministry of Education, Culture, Sport, Science and Technology of Japan, the Core Research for Evolutional Science and Technology of Japan Science and Technology Corporation, and the Mochida Memorial Foundation for Medical and Pharmaceutical Research.
The authors have no conflicting financial interests.
Submitted: 12 December 2005
Accepted: 10 August 2006
| REFERENCES |
|---|
|
|
|---|
1 Lund, A.H., and M. van Lohuizen. 2004. Polycomb complexes and silencing mechanisms. Curr. Opin. Cell Biol. 16:239246.[CrossRef][Medline]
2 Valk-Lingbeek, M.E., S.W.M. Bruggeman, and M. van Lohuizen. 2004. Stem cells and cancer: the polycomb connection. Cell. 118:409418.[CrossRef][Medline]
3 Iwama, A., H. Oguro, M. Negishi, Y. Kato, and H. Nakauchi. 2005. Epigenetic regulation of hematopoietic stem cell self-renewal by polycomb group genes. Int. J. Hematol. 81:294300.[CrossRef][Medline]
4 van der Lugt, N.M., J. Domen, K. Linders, M. van Roon, E. Robanus-Maandag, H. te Riele, M. van der Valk, J. Deschamps, M. Sofroniew, M. van Lohuizen, and A. Berns. 1994. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 8:757769.
5 Lessard, J., and G. Sauvageau. 2003. Bmi-1 determines proliferative capacity of normal and leukemic stem cells. Nature. 423:255260.[CrossRef][Medline]
6 Molofsky, A.V., R. Pardal, T. Iwashita, I.K. Park, M.F. Clarke, and S.J. Morrison. 2003. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature. 425:962967.[CrossRef][Medline]
7 Park, I.K., D. Qian, M. Kiel, M.W. Becker, M. Pihalja, I.L. Weissman, S.J. Morrison, and M.F. Clarke. 2003. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 423:302305.[CrossRef][Medline]
8 Iwama, A., H. Oguro, M. Negishi, Y. Kato, Y. Morita, H. Tsukui, H. Ema, T. Kamijo, Y. Katoh-Fukui, H. Koseki, et al. 2004. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product, Bmi-1. Immunity. 21:843851.[CrossRef][Medline]
9 Jacobs, J.J.L., K. Kieboom, S. Marino, R.A. DePinho, and M. van Lohuizen. 1999. The oncogene and Polycomb-group gene bmi1 regulates proliferation and senescence through the ink4a locus. Nature. 397:164168.[CrossRef][Medline]
10 Sharpless, N.E., and R.A. DePinho. 1999. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9:2230.[CrossRef][Medline]
11 Bruggeman, S.W.M., M.E. Valk-Lingbeek, P.P. van der Stoop, J.J.L. Jacobs, K. Kieboom, E. Tanger, D. Hulsman, C. Leung, Y. Arsenijevic, S. Marino, and M. van Lohuizen. 2005. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev. 19:14381443.
12 Molofsky, A.V., S. He, M. Bydon, S.J. Morrison, and R. Pardal. 2005. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev. 19:14321437.
13 Osawa, M., K. Hanada, H. Hamada, and H. Nakauchi. 1996. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cells. Science. 273:242245.[Abstract]
14 Takano, H., H. Ema, K. Sudo, and H. Nakauchi. 2004. Asymmetric division and lineage commitment at the level of hematopoietic stem cells: inference from differentiation in daughter cell and granddaughter cell pairs. J. Exp. Med. 199:295302.
15 Calvi, L.M., G.B. Adams, K.W. Weibrecht, J.M. Weber, D.P. Olson, M.C. Knight, R.P. Martin, E. Schipani, P. Divieti, F.R. Bringhurst, et al. 2003. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 425:841846.[CrossRef][Medline]
16 Zhang, J., C. Niu, L. Ye, H. Huang, X. He, W.G. Tong, J. Ross, J. Haug, T. Johnson, J.Q. Feng, et al. 2003. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 425:836841.[CrossRef][Medline]
17 Arai, F., A. Hirao, M. Ohmura, H. Sato, S. Matsuoka, K. Takubo, K. Ito, G.Y. Koh, and T. Suda. 2004. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 118:149161.[CrossRef][Medline]
18 Kiel, M.J., O.H. Yilmaz, T. Iwashita, O.H. Yilmaz, C. Terhorst, and S.J. Morrison. 2005. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 121:11091121.[CrossRef][Medline]
19 Campisi, J. 2005. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 120:513522.[CrossRef][Medline]
20 Allsopp, R.C., G.B. Morin, R. DePinho, C.B. Harley, and I.L. Weissman. 2003. Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood. 102:517520.
21 Allsopp, R.C., G.B. Morin, J.W. Horner, R. DePinho, C.B. Harley, and I.L. Weissman. 2003. Effect of TERT over-expression on the long-term transplantation capacity of hematopoietic stem cells. Nat. Med. 9:369371.[CrossRef][Medline]
22 Stepanova, L., and B.P. Sorrentino. 2005. A limited role for p16Ink4a and p19Arf in the loss of hematopoietic stem cells during proliferative stress. Blood. 106:827832.
23 Katayama, K., K. Wada, H. Miyoshi, K. Ohashi, M. Tachibana, R. Furuki, H. Mizuguchi, T. Hayakawa, A. Nakajima, T. Kadowaki, et al. 2004. RNA interfering approach for clarifying the PPARgamma pathway using lentiviral vector expressing short hairpin RNA. FEBS Lett. 560:178182.[CrossRef][Medline]
Related Article
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|